Screening for diabetes

British Medical Journal

Volumn 335, Issue 7618, 2007, Pages 457-458

  Stolk, Ronald P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EDITORIAL; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; MASS SCREENING; MENTAL STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYDIPSIA; POLYURIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCREENING TEST; WEIGHT REDUCTION;

DIABETES MELLITUS; HUMANS; MASS SCREENING; STRESS, PSYCHOLOGICAL;

EID: 34548659495     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39323.395336.BE     Document Type: Editorial

References (10)

1. Eborall HC, Griffin SJ, Prevost AT, Kinmonth A-L, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION Cambridge randomised controlled trial. BMJ 2007 doi: 10.1136/bmj.39303.723449.55.
2. Eborall H, Davies R, Kinmonth A-L, Griffin S, Lawton J. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION Cambridge randomised trial. BMJ 2007 doi: 10.1136/bmj.39308.392176.BE.
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
4. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000;23:1563-80.
5. Jansen PGM, Gorter KJ, Stolk RP, Rutten GEHM. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese. The ADDITION Netherlands study. Prim Care Diabet 2007;1:69-74.
6. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ 2001;322:986-8.
7. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24(suppl 3):S6-11.
8. Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of the evidence for the US preventive services task force. Am J Prev Med 2003;25:151-8.
9. Thoolen BJ, de Ridder DT, Bensing JM, Gorter KJ, Rutten GE. Psychological outcomes of patients with screen-detected type 2 diabetes: the influence of time since diagnosis and treatment intensity. Diabetes Care 2006;29:2257-62.
10. Glumer C, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmonth AL, et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-44.